ScientiaCME The roadmap to optimizing geographic atrophy care: updates in risk assessment, treatment, and care pathways in late-stage age-related macular degeneration
Cost: FreeView Offer chevron_right
Activity Description / Statement of Need:
In this online, self-learning activity:
Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over the age of 50 years. In the early stages of disease, vision may be gray, hazy, or distorted. As the disease progresses, retinal deterioration can lead to irreversible, bilateral loss of central vision. In the US alone, an estimated 18.3 million people are living with early-stage ARMD, and 1.5 million people are living with late-stage AMD, representing 11.6% and 0.9% of all adults older than 40 years, respectively. In addition to the burden of disability caused by blindness, AMD is also associated with substantial societal and economic costs. In the US, vision loss and blindness incur an economic burden of $134 billion annually, of which $36 billion is attributable to indirect costs such as loss of productivity, injury, and unemployment.
The following HCPs: comprehensive ophthalmologists and retinal specialists; physician assistants, and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with AMD.